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INTRODUCTION
Photodynamic therapy (PDT) is one of the most important recent ad-
vances for treatment of choroidal neovascularization (CNV) associated with
many diseases, especially age-related macular degeneration (AMD)(1-2). La-
tely, the association of PDT and intravitreal injection of triamcinolone
acetonide has shown potential short-term benefit in the management of
CNV secondary to AMD(3-5). Although effective in the treatment of some
diseases of the posterior segment, intraocular triamcinolone can cause side
effects, especially ocular hypertension, cataract and pseudohypopyon(6-9).
We describe a severe complication after photodynamic therapy (PDT)
and intravitreal triamcinolone for a presumed choroidal neovascularization
in age-related macular degeneration.
CASE REPORT
A 84-year-old white male, from Luís Alves (SC), was referred with a 7-
day complaint of decreased central vision in the left eye. His best-corrected
visual acuity was 20/30 in the right eye and 20/70 in the left eye. Slit lamp
biomicroscopy showed a mild nuclear cataract in both eyes. Intraocular
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The purpose is to report a complication after photodynamic therapy (PDT)
and intravitreal triamcinolone for a presumed choroidal neovascularization
in age-related macular degeneration. Photodynamic therapy and intravitreal
triamcinolone were used in an 84-year-old man with choroidal neovascu-
larization in the left eye. Forty-five days after therapy, the patient returned
with a severe necrotizing uveitis in the posterior pole and vitritis. Laboratory
investigation disclosed a high anti-Toxoplasma IgG titer. Therapy with
pyrimethamine, sulfadiazine and folinic acid resulted in total lesion healing
although central vision was lost. Intravitreal triamcinolone may have had
an influence on the exacerbation of retinochoroiditis in the posterior pole
of the patient. Although rare, this complication may not be disregarded in
the cases that require intraocular corticosteroids for treatment of several
conditions, especially in patients who had previously suffered from
toxoplasmosis infection.
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pressure was 14 mmHg and 13 mmHg, respectively. Eye fun-
dus examination disclosed no abnormalities in the right eye; in
the left eye, there was a juxtafoveal yellow-white lesion of less
than one disc area and poorly defined margins; there were also
a slight sensory retinal detachment around the lesion and a
small atrophic area inferior to it. Fluorescein angiography sho-
wed an early hyperfluorescence of the juxtafoveal lesion with
intense leakage and late pooling of fluorescein under the
detached retina (Figure 1).
A diagnosis of choroidal neovascularization secondary to
age-related macular degeneration was established. The pa-
tient was submitted to PDT using verteporfin. An adjuvant
intravitreal injection of 4 mg triamcinolone acetonide was per-
formed 4-days after PDT. Forty-five days after the injection,
the patient returned with a 15-day history of intense visual
deficit in the treated eye. His best-corrected visual acuity was
20/30 in the right eye and counting fingers at 2 meters in the
left eye. Slit lamp biomicroscopy showed mild nuclear cataract
in both eyes and vitreal cells 2+ in the left eye. Intraocular
pressure was 15 mmHg and 12 mmHg, respectively. Fundos-
copy was unremarkable in the right eye; in the left eye, there
was a moderate vitritis associated with a severe retinochoroidi-
tis affecting the whole macula and a pale optic disc (Figure 2).
Laboratory investigation disclosed an IgG anti-Toxoplasma
titer of 250 IU. The patient was treated with pyrimethamine,
sulfadiazine and folinic acid and, after three weeks, the vi-
treous was clearer and there was almost complete lesion hea-
ling. As the patient could not continue taking the medication
due to gastric intolerance, sulfamethoxazole and trimethoprim
were given daily for other four weeks, followed by 3 times a
Figure 1 - Left fundus of the patient prior to the treatment. Left: there is a yellow-white juxtafoveal lesion with adjacent sensory retinal detachment
and a small atrophic area inferior to it. Right: late fluorescein angiogram reveals intense leakage of the lesion and pooling in the detached area.
Figure 2 - Same eye 45 days after PDT and intravitreal triamcinolone. Left: there is a moderate vitritis associated with a severe macular active
retinochoroiditis and a pale optic disc. Right: late phase angiogram shows diffuse leakage in the macula.
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week continuously. There were no relapses till the last exa-
mination, performed 14 months after starting toxoplasmosis
therapy. Final best-corrected visual acuity was 20/30 in the
right eye and counting fingers at 2 meters in the left eye.
DISCUSSION
Age-related macular degeneration (AMD) is a very common
cause of legal blindness in the United States among people 40
years of age and older(10). In Brazil, this disease is also frequent
and it can provoke a bilateral visual impairment among older
people(11).
Although neovascular or exudative AMD is far less common
than nonneovascular or nonexudative AMD, it usually causes a
more severe visual loss. The management of neovascular AMD
is still controversial and includes laser photocoagulation, subma-
cular surgery, PDT and pharmacologic intervention(12).
Nowadays, PDT is considered one of the most useful
therapies for exudative AMD because it promotes a selective
destruction of CNV with preservation of the overlying neuro-
sensory retina(1-2).
Recently, combined PDT and intravitreal triamcinolone ace-
tonide have been used for CNV secondary to AMD, with promi-
sing results, particularly when applied as first-line therapy(3-5).
Demographics, medical history, ophthalmologic examina-
tion and fluorescein angiography were suggestive that the
cause of visual loss in the left eye of the patient was CNV due to
AMD. And this is the reason that combined PDT and intra-
vitreal triamcinolone were used.
Otherwise, the possibility of misdiagnosis of choroidal
neovascularization must not be excluded. The supposed sub-
retinal neovascular membrane could be, in fact, an active toxo-
plasmosis satellite lesion adjacent to a previous small atrophic
scar (Figure 1).
A highly positive IgG anti-Toxoplasma titer and a good
response to specific therapy show that toxoplasmosis was
probably involved in the pathogenesis of this devastating
manifestation.
In addition, it is known that corticosteroids must not be
used without simultaneous antimicrobial cover for treatment
of ocular toxoplasmosis and periocular injections are contrain-
dicated to avoid local immunosuppression and uncontrollable
disease(13).
Although unusual, the related complication may not be
neglected in patients that require intraocular corticosteroids
for treatment of several conditions, especially in patients with
previous ocular toxoplasmosis findings.
CONCLUSION
Intravitreal triamcinolone may have had an influence on
the exacerbation of retinochoroiditis in the posterior pole of
the patient. This complication may not be disregarded in the
cases that need intraocular corticosteroids for treatment of
several diseases, especially in patients who had previously
suffered from toxoplasmosis infection.
RESUMO
O objetivo é relatar complicação após terapia fotodinâmica
(PDT) e triancinolona intravítrea para presumida neovasculari-
zação de coróide em degeneração macular relacionada à idade.
A terapia fotodinâmica e triancinolona intravítrea foram utili-
zados em paciente de 84 anos, do sexo masculino, com neovas-
cularização de coróide no olho esquerdo. Quarenta e cinco dias
após o tratamento, o paciente retornou com grave retinite ne-
crosante do pólo posterior e vitreíte. Investigação laboratorial
indicou alto título de IgG anti-Toxoplasma. Tratamento com
pirimetamina, sulfadiazina e ácido folínico levaram à total cicatri-
zação da lesão embora a visão central tenha sido comprometida.
Conclui-se que a triancinolona intravítrea pode ter influenciado
na exacerbação da retinocoroidite no pólo posterior do pacien-
te. Embora rara, esta complicação não pode ser descartada nos
casos que necessitem corticóide intra-ocular para tratamento de
várias doenças, principalmente em pacientes que tenham tido
surtos prévios de toxoplasmose ocular.
Descritores: Uveíte; Toxoplasmose ocular; Triancinolona/
efeitos adversos; Neovascularização coroidal/terapia; Corpo
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